Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...

Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...

Sanofi will keep launching new medicines across Europe under Trump’s MFN policy, possibly at higher prices, its CFO says.

AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in ...

AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...

Aspen Neuroscience raises ~$141M and Bambusa ~$169M in Nasdaq IPOs, pushing 2026 biotech IPO haul to ~$8B across 29 deals.

Eli Lil­ly once again dom­i­nat­ed rev­enue ex­pec­ta­tions, blow­ing past Wall Street’s es­ti­mates by about $2 bil­lion.

Mer­ck’s head of R&D Dean Li be­lieves he’s out­foxed his com­pe­ti­tion for the next gen­er­a­tion of on­col­o­gy drugs, ...

Vertex, Kindeva and Convatec pledge £1B+ for UK sites in Healey’s first Budget; Teva closes NJ plant; Regeneron extends ...

FDA releases CRISPR medicine framework for personalized gene therapies, building on Baby KJ's case. Danaher's Kassim flags ...

For­ma­tion Bio, an AI-fo­cused biotech that ac­quires out­side as­sets, de­vel­ops them and then hands them off, has raised ...

HHS on Wednes­day said it will stop en­forc­ing a ban on the com­pound­ing of cer­tain pop­u­lar pep­tides used for well­ness pur­pos­es while the FDA works on rule­mak­ing to ad­dress the sub­stances ...